Putti Sabrina, Giovinazzo Alessandro, Merolle Matilde, Falchetti Maria Laura, Pellegrini Manuela
Institute of Biochemistry and Cell Biology, IBBC-CNR, Campus Adriano Buzzati Traverso, Via Ercole Ramarini, 32, Monterotondo Scalo, 00015 Rome, Italy.
Cancers (Basel). 2021 Nov 1;13(21):5498. doi: 10.3390/cancers13215498.
ATM is one of the principal players of the DNA damage response. This protein exerts its role in DNA repair during cell cycle replication, oxidative stress, and DNA damage from endogenous events or exogenous agents. When is activated, ATM phosphorylates multiple substrates that participate in DNA repair, through its phosphoinositide 3-kinase like domain at the 3'end of the protein. The absence of ATM is the cause of a rare autosomal recessive disorder called Ataxia Telangiectasia characterized by cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility, and radiation sensitivity. There is a correlation between the severity of the phenotype and the mutations, depending on the residual activity of the protein. The analysis of patient mutations and mouse models revealed that the presence of inactive ATM, named ATM kinase-dead, is more cancer prone and lethal than its absence. mutations fall into the whole gene sequence, and it is very difficult to predict the resulting effects, except for some frequent mutations. In this regard, is necessary to characterize the mutated protein to assess if it is stable and maintains some residual kinase activity. Moreover, the whole-genome sequencing of cancer patients with somatic or germline mutations has highlighted a high percentage of mutations in the phosphoinositide 3-kinase domain, mostly in cancer cells resistant to classical therapy. The relevant differences between the complete absence of ATM and the presence of the inactive form in in vitro and in vivo models need to be explored in more detail to predict cancer predisposition of A-T patients and to discover new therapies for ATM-associated cancer cells. In this review, we summarize the multiple discoveries from humans and mouse models on ATM mutations, focusing into the inactive versus null ATM.
ATM是DNA损伤反应的主要参与者之一。这种蛋白质在细胞周期复制、氧化应激以及内源性事件或外源性因素导致的DNA损伤期间发挥其在DNA修复中的作用。当被激活时,ATM通过其蛋白质3'端的磷酸肌醇3激酶样结构域磷酸化多个参与DNA修复的底物。ATM的缺失是一种罕见的常染色体隐性疾病——共济失调毛细血管扩张症的病因,其特征为小脑变性、毛细血管扩张、免疫缺陷、癌症易感性和辐射敏感性。表型的严重程度与突变之间存在相关性,这取决于蛋白质的残余活性。对患者突变和小鼠模型的分析表明,存在无活性的ATM(称为ATM激酶失活)比其缺失更易患癌症且具有致死性。突变遍布整个基因序列,除了一些常见突变外,很难预测其产生的影响。在这方面,有必要对突变蛋白进行表征,以评估其是否稳定并保持一些残余激酶活性。此外,对患有体细胞或种系突变的癌症患者进行的全基因组测序突出显示,磷酸肌醇3激酶结构域中的突变比例很高,主要存在于对传统疗法耐药的癌细胞中。需要更详细地探索体外和体内模型中完全不存在ATM与存在无活性形式之间的相关差异,以预测共济失调毛细血管扩张症患者的癌症易感性,并发现针对ATM相关癌细胞的新疗法。在这篇综述中,我们总结了来自人类和小鼠模型关于ATM突变的多项发现,重点关注无活性与缺失ATM的情况。